How frequently do artesunate's major side effects occur?

How common are the major side effects of artesunate?

Artesunate is used for severe malaria and is given intravenously. The drug's most frequent serious adverse effect is delayed hemolytic anemia, which appears 7–21 days after treatment in roughly 20–30 percent of patients. Post-artesunate delayed hemolysis (PADH) is linked to the clearance of once-infected red blood cells and is usually self-limited.

How does delayed hemolysis compare with other side effects?

Neutropenia occurs in about 5–10 percent of treated patients and may require blood-count monitoring. Acute kidney injury is reported in 3–8 percent of cases, especially among those with heavy parasite loads. Hypersensitivity reactions, including rash and bronchospasm, arise in fewer than 2 percent of recipients.

What happens if hemolysis is severe?

When hemoglobin drops sharply, transfusion is required in less than 5 percent of PADH cases. Most patients recover within four weeks without long-term sequelae.

When do clinicians check blood counts after treatment?

Guidelines recommend hemoglobin checks at baseline, day 7, and day 14 to catch delayed anemia early.

How does artesunate compare with quinine in terms of safety?

Artesunate produces fewer episodes of hypoglycemia and cardiac arrhythmias than quinine, but it carries the unique risk of delayed hemolysis that quinine does not share.

Who makes artesunate and when does the patent expire?

Artesunate is manufactured by several generic firms; the original product patents have expired, allowing broader generic supply.

[1] https://www.drugpatentwatch.com